QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:TMDX

TransMedics Group (TMDX) Stock Forecast, Price & News

$79.40
+4.64 (+6.21%)
(As of 06/6/2023 ET)
Compare
Today's Range
$74.47
$80.18
50-Day Range
$66.23
$88.73
52-Week Range
$24.01
$90.15
Volume
1.13 million shs
Average Volume
533,362 shs
Market Capitalization
$2.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.29

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
9.0% Downside
$72.29 Price Target
Short Interest
Bearish
10.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of TransMedics Group in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.56 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.62) to ($0.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

947th out of 981 stocks

Electromedical Equipment Industry

20th out of 21 stocks


TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
TransMedics: Expensive, But High Potential
TransMedics Group (NASDAQ:TMDX) Sees Large Volume Increase
TransMedics Group (NASDAQ:TMDX) Shares Gap Down to $74.02
From -60% Account to Doubling His Money?
After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.
Is TransMedics Group Stock a Buy on the Dip?
Q1 2023 Transmedics Group Inc Earnings Call
TransMedics Reports First Quarter 2023 Financial Results
See More Headlines

TMDX Price History

TMDX Company Calendar

Last Earnings
5/01/2023
Today
6/06/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$72.29
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$45.00
Forecasted Upside/Downside
-9.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-36,230,000.00
Pretax Margin
-23.70%

Debt

Sales & Book Value

Annual Sales
$93.46 million
Book Value
$5.87 per share

Miscellaneous

Free Float
30,373,000
Market Cap
$2.60 billion
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Waleed H. HassaneinWaleed H. Hassanein
    President, Chief Executive Officer & Director
  • John F. CareyJohn F. Carey
    Vice President-Operations
  • Stephen GordonStephen Gordon
    Chief Financial Officer, Secretary & Treasurer
  • Mark Anderson
    Senior Director-Technology Development
  • Phillip Camp
    Chief Medical Officer













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

7 Wall Street analysts have issued 12 month price objectives for TransMedics Group's shares. Their TMDX share price forecasts range from $45.00 to $90.00. On average, they predict the company's stock price to reach $72.29 in the next year. This suggests that the stock has a possible downside of 9.4%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2023?

TransMedics Group's stock was trading at $61.72 at the beginning of 2023. Since then, TMDX stock has increased by 29.2% and is now trading at $79.77.
View the best growth stocks for 2023 here
.

Are investors shorting TransMedics Group?

TransMedics Group saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,300,000 shares, an increase of 35.2% from the April 30th total of 2,440,000 shares. Based on an average daily trading volume, of 635,600 shares, the days-to-cover ratio is presently 5.2 days.
View TransMedics Group's Short Interest
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings data on Monday, May, 1st. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.17. The firm had revenue of $41.60 million for the quarter, compared to the consensus estimate of $36.05 million. TransMedics Group had a negative net margin of 23.76% and a negative trailing twelve-month return on equity of 18.30%. The firm's revenue was up 161.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.38) earnings per share.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2023 earnings guidance on Monday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$170.00 million, compared to the consensus revenue estimate of $157.66 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (10.00%), BlackRock Inc. (6.93%), Macquarie Group Ltd. (5.36%), Fred Alger Management LLC (3.51%), Allspring Global Investments Holdings LLC (2.94%) and Credit Suisse AG (2.53%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $79.77.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $2.60 billion and generates $93.46 million in revenue each year. The company earns $-36,230,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -